The cloud software that decides whether a price drives profit or a compliance problem - for the world's biggest drugmakers and chipmakers.
Nobody grows up dreaming about gross-to-net accounting. Yet somewhere inside every large pharmaceutical company, a system has to guarantee that a drug is sold at the right price, to the right payer, under the right regulation - across dozens of countries, thousands of contracts, and a tangle of rebates and discounts that shift by the quarter. For 150-plus of the world's leading manufacturers, that system is Model N.
Founded in 1999 and headquartered in Redwood City, California, Model N builds cloud revenue-management software for two very different worlds: life sciences (pharmaceutical and medical-technology firms) and high tech (semiconductor and electronics manufacturers). Its platform automates the unglamorous but mission-critical machinery of commercialization - pricing, quoting, contracting, rebates, incentives, and regulatory compliance.
The company frames its purpose plainly: helping customers "know and grow their true top line and maximize every revenue moment at speed and scale." In practice, that means catching the money that quietly leaks out of large enterprises - the rebate overpaid, the chargeback missed, the government price miscalculated, the tender lost to a slow quote.
It is essential software that almost no consumer will ever see. And in 2024, that durability drew a $1.25 billion check from Vista Equity Partners to take the company private.
In regulated, channel-heavy industries, revenue rarely moves in a straight line. A drug or a chip passes through distributors, wholesalers, group purchasing organizations, and payers, each attached to its own pricing rules, rebates, chargebacks, and price protections. Errors compound silently, and the losses - collectively called revenue leakage - can run into the tens of millions.
Model N's answer is to put that entire lifecycle under one governed, auditable system. Pricing decisions, rebate calculations, and contract terms live in one place, checked against regulatory requirements like U.S. government pricing, Medicaid, the 340B discount program, and Sarbanes-Oxley controls.
Its customers are the pricing, contracting, finance, and compliance teams inside large manufacturers - Johnson & Johnson, AstraZeneca, Novartis, Merck, Moderna, and Abbott on the life-sciences side; AMD, Microchip Technology, and ON Semiconductor on the high-tech side.
What sets Model N apart is less flash than depth. General CPQ and revenue tools can quote and bill. Few encode 25 years of accumulated regulatory knowledge - the arcane rules of Medicaid rebates or 340B eligibility - into working software. That expertise is slow to build and hard to rip out, which is exactly why marquee customers stay.
Model N consolidates its offerings into industry Revenue Clouds, layered with data and analytics. The through-line: manage the whole path from price to payment, without switching systems.
Pricing, contracts, rebates, government pricing, Medicaid claims, and provider/payer management for regulated life-sciences companies.
Channel data management, deal and price intelligence, rebate and market-development-fund management for high-tech manufacturers.
Automates U.S. government pricing calculations, Medicaid claims processing, and state price-transparency reporting.
Compliance and visibility for the 340B drug-discount program, strengthened by the Kalderos acquisition and its Truzo platform.
Handles complex global tenders, quoting, and deal approvals for life-sciences and medtech commercial operations.
Surfaces pricing, rebate, and channel insights across the revenue lifecycle to inform better commercial decisions.
150+ leading manufacturers across more than 120 countries. In a recent milestone, Johnson & Johnson agreed to migrate from on-premise revenue management to Model N Revenue Cloud for Life Sciences.
Zack Rinat, Yarden Malka, and Ali Tore start the company to fix how manufacturers manage revenue. Rinat came from Sun Microsystems and the NetDynamics Application Server.
Model N adds Medicaid claims processing to its Revenue Management Suite, deepening its pharma-compliance focus long before it was a mainstream category.
Acquires Azerity, extending pricing and quoting into high-tech companies - the beginning of its dual-industry footprint.
Model N goes public under the ticker MODN.
Offerings consolidate into Revenue Cloud for Life Sciences and Revenue Cloud for High Tech.
Vista completes a $1.25 billion take-private at $30.00 per share; Model N delists from the NYSE.
Acquires Kalderos and its Truzo platform to expand 340B and gross-to-net capabilities with real-time, claims-level visibility.
It provides cloud revenue-management software that automates pricing, quoting, contracting, rebates, incentives, and regulatory compliance for pharmaceutical, medtech, semiconductor, and high-tech manufacturers.
Vista Equity Partners, which acquired the company in a $1.25 billion all-cash take-private completed in June 2024.
More than 150 leading manufacturers across 120+ countries, including Johnson & Johnson, AstraZeneca, Novartis, Merck, Moderna, Abbott, AMD, and Microchip Technology.
It was founded in 1999 by Zack Rinat, Yarden Malka, and Ali Tore, and is headquartered in Redwood City, California.
Its depth in regulated pricing and compliance - Medicaid, government pricing, 340B, global tenders - encoded over 25 years, creating high switching costs versus general revenue or CPQ tools.